Europe Demonstrates better anti-tumor efficacy than approved benchmark antibodies in preclinical tumor models. | --- | --- | --- | --- | --- | --- | --- | --- | |------------------|----------------------|--------|-----------------------------------|----------------|-------|-----------------------|----------------| | | | | | | | | | | | IPH6101/SAR'579 | | IPH6401/SAR'514 | IPH62 | | OPTION | | | Ongoing programs | CD123 Phase 1 in AML | | Progression towards IND | B7-H3 Research | | 2 undisclosed targets | ...

Innate Pharma S.A. (NASDAQ:IPHA) Q4 2022 Earnings Conference Call March 23, 2023 9:00 AM ET Company Participants Henry Wheeler - Head, Investor Relations Mondher Mahjoubi - Chief Executive Officer Joyson Karakunnel - Executive Vice President and Chief Medical Officer Yannis Morel - Executive Vice President-Business Development and Product Portfolio Strategy Frederic Lombard - Senior Vice President, Chief Financial Officer Conference Call Participants Carly Kenselaar - Citigroup Daina Graybosch - SVB Securit ...

Exhibit 99.1 Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update MARSEILLE, France--(BUSINESS WIRE)--March 23, 2023--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today reported its consolidated financial results1 for the year ending December 31, 2022. The consolidated financial statements are attached to this press release. "In 2022 we made important progress in our pipeline, both on our clinical and preclinical projects as well as maintaining a ...

Innate Pharma S.A. (NASDAQ:IPHA) Q3 2022 Earnings Conference Call November 14, 2022 8:00 AM ET Company Participants Henry Wheeler – Head-Investor Relations Mondher Mahjoubi – Chief Executive Officer Joyson Karakunnel – Executive Vice President and Chief Medical Officer Yannis Morel – Executive Vice President-Business Development and Product Portfolio Strategy Conference Call Participants Yigal Nochomovitz – Citigroup Daina Graybosch – SVB Securities Swayampakula Ramakanth – HCW Operator Hello, and thank you ...

Q3 2022 Financial Results and Business Update November 14, 2022 PARIS: IPH.PA NASDAQ: IPHA © 2021 Innate Pharma. All rights reserved. Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the "Company") solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document contains forward-looking statements. The use of certain words, including "believ ...

Innate Pharma S.A. (NASDAQ:IPHA) First Half 2022 Financial Results and Business Update September 15, 2022 8:00 AM ET Company Participants Henry Wheeler – Investor Relations Mondher Mahjoubi – Chief Executive Officer Joyson Karakunnel – Executive Vice President and Chief Medical Officer Yannis Morel – Executive Vice President-Business Development and Product Portfolio Strategy Frédéric Lombard – Chief Financial Officer Conference Call Participants Carly Kenselaar – Citi Daina Graybosch – SVB Securities Nick ...

Half Year 2022 Financial Results and Business Update September 15, 2022 PARIS: IPH.PA NASDAQ: IPHA © 2021 Innate Pharma. All rights reserved. Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the "Company") solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document contains forward-looking statements. The use of certain words, including ...

INNATE PHARMA SA HALF-YEAR FINANCIAL REPORT JUNE 30, 2022 INNATE PHARMA S.A. French société anonyme governed by an Executive Board and a Supervisory Boardé with a share capital of 3,995,355.70 euros composed of 79,893,019 ordinary shares, and 14,095 preferred shares with a nominal value of 0.05 euros each Registered office: 117, Avenue de Luminy, F-13009 Marseille, France Registered with the Company and Trade Register of Marseille under number 424 365 336 The following interim condensed consolidated financi ...

Innate Pharma SA (NASDAQ:IPHA) Q1 2022 Earnings Conference Call May 10, 2022 8:00 AM ET Company Participants Henry Wheeler - VP and Head of IR Mondher Mahjoubi - Chairman of Executive Board and CEO Joyson Karakunnel - Executive VP and Chief Medical Officer Yannis Morel - Executive VP of Product Portfolio Strategy and Business Development and Member of Executive Board Conference Call Participants Daina Graybosch - SVB Leerink Olga Smolentseva - Bryan Garnier Jingming Chen - Evercore Arthur He - H.C. Wainwrig ...

Company Overview March 2022 PARIS: IPH.PA NASDAQ: IPHA © 2020 Innate Pharma. All rights reserved. Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the "Company") solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document contains forward-looking statements. The use of certain words, including "believe," "potential," "expect" and "will" ...